Efficacy of rivastigmine for cognitive symptoms in parkinson disease with dementia

Neurologist

Volumn 15, Issue 4, 2009, Pages 234-237

  Almaraz, Amy C ^a   Driver Dunckley, Erika D ^a   Woodruff, Bryan K ^a   Wellik, Kay E ^a   Caselli, Richard J ^a   Demaerschalk, Bart M ^a   Adler, Charles H ^a   Caviness, John N ^a   Wingerchuk, Dean M ^a  

^a MAYO CLINIC   (United States)

Author keywords

Cholinesterase inhibitors; Critically appraised topic; Dementia; Evidence based medicine; Parkinson disease; Rivastigmine

Indexed keywords

ACETYLCHOLINE; CARBAMIC ACID DERIVATIVE; CHOLINESTERASE INHIBITOR; PLACEBO; RIVASTIGMINE;

AGED; ARTICLE; BRAIN; CASE REPORT; COGNITIVE DEFECT; DIFFUSE LEWY BODY DISEASE; DISEASE COURSE; DRUG EFFECT; HUMAN; MALE; META ANALYSIS; METABOLISM; NEUROPSYCHOLOGICAL TEST; ORAL DRUG ADMINISTRATION; PARASITOLOGY; PARKINSON DISEASE; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT; TREATMENT OUTCOME;

ACETYLCHOLINE; ADMINISTRATION, ORAL; AGED; BRAIN; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; DISEASE PROGRESSION; HUMANS; LEWY BODY DISEASE; MALE; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; PHENYLCARBAMATES; PLACEBOS; TREATMENT OUTCOME;

EID: 70349763571     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: 10.1097/NRL.0b013e3181a968df     Document Type: Article

References (18)

1. Van Den Eeden SK, Tanner CM, Berstein AL, et al. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol. 2003; 157:1015-1022
2. Nakano I, Hirano A. Parkinson's disease: neuron loss in the nucleus basalis without concomitant Alzheimer's disease. Ann Neurol. 1984;15:415-418
3. Dubois B, Pillon B. Dementia in Parkinson's disease. In: Wolters EC, Sheltens PH, Berendse HW, eds. Mental Dysfunction in Parkinson's Disease II. Utrecht, The Netherlands: Academic Pharmaceutical Productions; 1999: 165-176
4. Jellinger KA, Bancher CH, Fischer P. Neuropathological correlates of mental dysfunction in Parkinson's disease. In: Wolters EC, Scheltens PH, eds. Mental Dysfunction in Parkinson's Disease. Dordrecht, The Netherlands: ICG Printing; 1994;141-161
5. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's Disease. N Engl J Med. 2004;351:2509 -2518
6. Leroi I, Brandt J, Reich SG, et al. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. Int J Geriatr Psychiatry. 2004;19:1- 8
7. Ravina B, Putt M, Siderowf A, et al. Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry. 2005;76:934 -939
8. Available at: www.aan.com/go/practice/guidelines. Accessed February 16, 2009
9. Maidment I, Fox C, Boustani M. Cholinesterase inhibitors for Parkinson's disease dementia. Cochrane Database Syst Rev. 2006:CD004747
10. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry. 1988;51:745- 752
11. Diagnostic and Statistical Manual of Mental Disorders. DMS-IV. 4th ed. Washington, DC: American Psychiatric Association; 1994
12. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141:1356 -1364
13. Schneider LS, Olin JT, Doody RS, et al. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change: the Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11(suppl 2):S22-S32
14. Clegg A, Bryant J, Nicholson T, et al. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review. Health Technol Assess. 2001;5:1-137
15. Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56: 1154-1166
16. Stern RG, Mohs RC, Davidson M, et al. A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry. 1994;151:390 -396
17. Sabbagh MN, Sandhu SS, Farlow MR, et al. Correlation of clinical features to argyrophilic grains at autopsy. Alz Dis Assoc Disorders. 2009
18. Caviness JN, Driver-Dunckley ED, Connor DJ, et al. Defining mild cognitive impairment in Parkinson's disease. Mov Disord. 2007;22:1272-1277